Kolexia
Crequit Jacky Pneumologie
Crequit Jacky
Pneumologie
Centre Hospitalier de Beauvais
Beauvais, France
61 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire à petites cellules Carcinome pulmonaire non à petites cellules Récidive tumorale locale Carcinome épidermoïde Effets secondaires indésirables des médicaments Métastase tumorale Adénocarcinome Perte de poids

Collaborateurs

Voir plus
Chouaid Christos
Chouaid Christos
Centre Hospitalier Intercommunal Créteil, Créteil, France
Falchero Lionel
Falchero Lionel
Centre Hospitalier de Villefranche, Gleizé, France
Le Caer Herve
Le Caer Herve
Centre Hospitalier de Saint Brieuc, Saint-Brieuc, France
Vergnenegre Alain
Vergnenegre Alain
Hôpital Dupuytren, Limoges, France

Industries

Voir plus
AstraZeneca
5 collaboration(s)
Dernière en 2020
B3TSI
4 collaboration(s)
Dernière en 2021
Janssen
4 collaboration(s)
Dernière en 2023
MSD
1 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
1035P A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017)
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
Early mortality in real-life nationwide epidemiological study on lung cancer in non-academic French public hospitals.
2022 ASCO Annual Meeting I   02 juin 2022
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials.
Lung cancer (Amsterdam, Netherlands)   09 septembre 2021
ALK-2016-CPHG: étude observationnelle prospective multicentrique en vie réelle de cancers bronchiques réarrangés ALK ou ROS1 traités par crizotinib
25e Congrès de pneumologie de langue française   01 janvier 2021
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
The Lancet. Oncology   23 septembre 2020
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01).
Cancer management and research   27 décembre 2019
P1.01-039 Does Distance between Chest and Surgery Departments Impact Outcome in Lung Cancer Patients? Results of KBP-2010-CPHG Study: Topic: Prognostic Factors, Treatment
Abstracts from the IASLC 17th World Conference on Lung Cancer   01 janvier 2017
CBPC: Randomized Study Comparing Two Strategies Carboplatin and Etoposide Topotecan in Patients With SCLC on the Second Row With Relapsed at Least Three Months After Initial Response to Chemotherapy With Platinum-etoposide 6 Cycles
Essai Clinique (CHU Angers)   22 avril 2016
Early mortality in lung cancer: French prospective multicentre observational study.
BMC pulmonary medicine   02 avril 2016
Real-life 2-year therapeutic strategies in the management of 525 small-cell lung cancers (SCLCs) in French general hospitals.
2015 ASCO Annual Meeting I   20 mai 2015